Across the world, there are multiple variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19). Among these variants, B.1.617.2 (Delta) variant is highly transmissible in indoor sports settings and within households. Therefore, a rapid and accurate test is needed to detect the presence of SARS-CoV-2 variants. This project aims to develop a more sensitive test strip to detect COVID-19 variant positive patients.
COVID-19 is a highly infectious respiratory disease that is caused by the SARS-CoV-2 virus. RT-qPCR is a nucleic acid testing that is widely adapted to confirm the infection. Point-of-care IgM/IgG testing strips have been adopted in some countries for screening and surveillance. However, these antibody testing strips are restricted to a positive/negative testing result.
While various community transmission mitigation tactics are being employed in regions across Canada, including stay home mandates, bans on public congregations, and provincial lockdown, public health experts and scientists agree that widespread availability of testing for COVID-19 would aid efforts in more accurately tracking the virus’ spread.
This project aims to develop a more sensitive serology test strip to detect COVID-19 positive patients. By utilizing genetic engineering technique, we will develop sensitive and accurate test strip which detects COVID-19 patient at early stage.
Infectious diseases from a variety of pathogens can lead to serious health conditions such as sepsis. To improve the prognosis and decrease the mortality rate of infectious diseases, point-of-care testing (POCT) of blood biomarkers is a critical approach. Testing of biomarkers such as C-reactive protein, IL-6 and procalcitonin could help identify the type of pathogen and classify the progression stage of infection.
Join a thriving innovation ecosystem. Subscribe now